GlobeNewswire·Nov 11, 2026, 4:05 PM ET

Beyond Air Reports Financial Results and Provides Corporate Update for the Quarter Ended September 30, 2026

XAIR

Beyond Air reported record quarterly revenue of $2.3 million for the period ended September 30, 2026, representing 28% year-over-year growth.
The PMA supplement for the second-generation LungFit PH system remains under FDA review with transport capability expected to drive market penetration pending approval.
The company reaffirmed revenue guidance of $8 million for calendar year 2026 $16–$18 million for calendar year 2027, including anticipated revenue from the second-generation system.
The company announced a definitive agreement for UNIVO Pharmaceutical Industries Ltd. to acquire its controlling interest in NeuroNOS Israel Ltd.
FDA Breakthrough Device Designation was received for LungFit GO to treat nontuberculous mycobacterial pulmonary disease, though development is paused until the second-generation LungFit PH launch.
Research and development expenses decreased to $1.6 million from $2.5 million in the prior year period due to completion of most second-generation system development.
Selling, general, and administrative expenses fell to $4.6 million from $4.9 million, driven by lower stock-based compensation offset by increased sales salaries.
Net loss attributed to common stockholders was $7.8 million, or $3.76 per share, compared to $7.9 million, or $24.98 per share, in the same period last year.
The company held $18.5 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026.
A conference call to discuss results was scheduled for November 11, 2026, at 4:30 p.m. ET.
The company is transitioning its fiscal year-end from March 31 to December 31, effective December 31, 2026.

Company: Beyond Air™
Keywords: Nasdaq:XAIR, Beyond Air™